An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum Refractory Cervical Carcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
July 19, 2018
End Date
December 3, 2018
Administered By
Duke Cancer Institute
Awarded By
Regeneron Pharmaceuticals, Inc.
Start Date
July 19, 2018
End Date
December 3, 2018